Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric CF Patients (CFALD)
Primary Purpose
Cystic Fibrosis, Cystic Fibrosis Liver Disease, Pancreatic Insufficiency Due to Cystic Fibrosis of Pancreas
Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Elastography
Sponsored by
About this trial
This is an interventional diagnostic trial for Cystic Fibrosis
Eligibility Criteria
Inclusion Criteria:
- Age <18 years
- Confirmed diagnosis of cystic fibrosis attending Pediatric cystic fibrosis (CF) Clinic at Children's Hospital, Winnipeg.
Exclusion Criteria:
- Children with age >18 years
Sites / Locations
- Winnipeg Children's Hospital
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
SIngle Arm
Arm Description
All patients undergo Elastography. This is a single arm study
Outcomes
Primary Outcome Measures
Evaluate the diagnostic properties of Shear wave Elastography
To evaluate the diagnostic properties of Shear wave Elastography (ElastPQ) in children with CF for detection of liver fibrosis.
Investigators will look at the values of shearwave elastography and see how it correlates with the fibrosis values obtained on liver biopsy as well as with AST/platelet ratio index
Secondary Outcome Measures
To compare findings/fibrosis of Transient Elastography vs ElastPQ
Investigators will compare degree of fibrosis on Transient Elastography vs Elast PQ to determine correlation .Some patients who have undergone liver biopsy will be correlated to liver fibrosis seen on biopsy.
This will allow investigators to determine if Shear wave elastography can reliably detect fibrosis in patients with CFALD
To compare the pancreatic insufficiency/ fecal elastase and transient elastography from pancreas.
Investigators will see how well pancreatic fibrosis correlates with Fecal Elastase values and pancreatic endocrine function .
This will let investigators know if Pancreatic elastography can help them in deciding which patients can have pancreatic insufficiency .
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03264950
Brief Title
Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric CF Patients
Acronym
CFALD
Official Title
The Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric Cystic Fibrosis Patients
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2017 (Anticipated)
Primary Completion Date
December 31, 2017 (Anticipated)
Study Completion Date
January 31, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Manitoba
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Diagnosis of hepatic fibrosis is challenging as specific tests for detection of fibrosis in pediatric Cystic Fibrosis associated liver disease (CFALD) have not been developed and existing investigations do not correlate well with presence or severity of disease. Using a Liver biopsy it is difficult to diagnose this condition because of the patchy nature of the disease. Investigators intend to identify hepatic and pancreatic fibrosis in Cystic Fibrosis patients using Elastography and correlate this with their biochemical markers as well as histological findings of patients who have undergone liver biopsy for diagnosis of CFALD.
Detailed Description
Liver disease is increasingly common in cystic fibrosis (CF). As new therapeutic options emerge, life expectancy increases and common hepatobiliary manifestations impact on quality of life and survival of CF patients. Hepatobiliary abnormalities in CF vary in nature and range from defects attributable to the underlying CFTR gene defect to those related to systemic disease and malnutrition. Today complications of liver disease represent the third most frequent cause of disease-related death in patients with CF.
Cystic fibrosis-associated liver disease (CFALD) belongs to the group of common symptoms of this disease; however, due to the lack of specific and sensitive CFALD diagnostic markers, the epidemiological data may be incomplete. According to various sources, the prevalence rate of CFALD, diagnosed on the basis of clinical, biochemical and imaging (ultrasonography) tests, is 2-37% in children and young adults.
Cirrhosis is a final, irreversible stage of liver damage that leads to the failure of the organ. While liver biopsy is considered the gold standard to assess for Hepatic Fibrosis; it is invasive and potentially life threatening. The prognosis and management of chronic liver disease depends on the extent and progression of liver fibrosis, which constitutes the most important predictor of disease outcome.
The gold standard for diagnosis and staging of liver fibrosis has been liver biopsy. In addition to being an invasive procedure with potential complications of bleeding and severe pain, sampling error is an intrinsic problem due to the small sample size in a heterogeneous process.7,8 Inter-observer variability also limits diagnostic consistency.9-11 The development of several blood markers such as platelets, hyaluronic acid, type IV collagen, aminotransferase/platelet ratio index (APRI) and algorithm based serum models (Fibro Index, FIB-4, and Fibro Test) have been used but are affected by factors unrelated to the liver.
In the last decade, methods to noninvasively quantify liver fibrosis have been developed. The first available method was transient elastography (TE).It is a single-element ultrasound transducer operating at 5 MHz built on the axis of a piston like vibrator. By pushing a button, low-frequency (50 Hz) transient vibrations are transmitted, and the generated elastic shear waves propagate through underlying tissues. Pulse-echo ultrasound acquisitions are used to follow the propagation of the shear wave and to measure its velocity .
Several studies have demonstrated a high accuracy of TE in identifying significant fibrosis (F> 2) and cirrhosis (F= 4) in patients. It is a novel diagnostic tool that offers a rapid, non-invasive method for monitoring HF. The device measures liver stiffness by transmitting a vibration to determine the velocity of an elastic shear wave propagated through liver tissue.
Studies have documented utility of transient elastography in cystic fibrosis patients to assess hepatic fibrosis and secondary complications.
Newer modalities like Shear wave elastography techniques have been implemented in conventional real-time ultrasound systems, and several studies have shown their accuracy in the assessment of liver fibrosis. Shear wave elastography relies on the generation of shear waves determined by the displacement of tissues induced by the force of a focused ultrasound beam or by external pressure. The shear waves are lateral waves, with a motion perpendicular to the direction of the force that has generated them. They travel slowly (between 1 and 10 m/s) and are rapidly attenuated by tissue. The propagation velocity of the shear waves correlates with the elasticity of tissue .
Compared with TE, these techniques have the advantage of B-mode image guidance; thus, they can allow the user to choose the best acoustic window for correctly performing an examination in real time.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis, Cystic Fibrosis Liver Disease, Pancreatic Insufficiency Due to Cystic Fibrosis of Pancreas
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Patients (<18 years) will be recruited from from the Children's Hospital Winnipeg CF clinic. Charts will be reviewed for demographic and clinical data including blood work. Each patient will undergo shear wave elastography by a trained operator.
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
SIngle Arm
Arm Type
Other
Arm Description
All patients undergo Elastography. This is a single arm study
Intervention Type
Diagnostic Test
Intervention Name(s)
Elastography
Intervention Description
an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.
Similarly an acoustic window will be selected for the pancreas as well
Primary Outcome Measure Information:
Title
Evaluate the diagnostic properties of Shear wave Elastography
Description
To evaluate the diagnostic properties of Shear wave Elastography (ElastPQ) in children with CF for detection of liver fibrosis.
Investigators will look at the values of shearwave elastography and see how it correlates with the fibrosis values obtained on liver biopsy as well as with AST/platelet ratio index
Time Frame
6 months
Secondary Outcome Measure Information:
Title
To compare findings/fibrosis of Transient Elastography vs ElastPQ
Description
Investigators will compare degree of fibrosis on Transient Elastography vs Elast PQ to determine correlation .Some patients who have undergone liver biopsy will be correlated to liver fibrosis seen on biopsy.
This will allow investigators to determine if Shear wave elastography can reliably detect fibrosis in patients with CFALD
Time Frame
6 months
Title
To compare the pancreatic insufficiency/ fecal elastase and transient elastography from pancreas.
Description
Investigators will see how well pancreatic fibrosis correlates with Fecal Elastase values and pancreatic endocrine function .
This will let investigators know if Pancreatic elastography can help them in deciding which patients can have pancreatic insufficiency .
Time Frame
6 months
10. Eligibility
Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age <18 years
Confirmed diagnosis of cystic fibrosis attending Pediatric cystic fibrosis (CF) Clinic at Children's Hospital, Winnipeg.
Exclusion Criteria:
Children with age >18 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Quais Mujawar
Phone
204-787-4950
Email
qmujawar@exchange.hsc.mb.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Vini Deora
Phone
204-787-4956
Email
vdeora@exchange.hsc.mb.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Quais Mujawar
Organizational Affiliation
University of Manitoba
Official's Role
Principal Investigator
Facility Information:
Facility Name
Winnipeg Children's Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3A 1S1
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Quais Mujawar
Phone
204-787-4950
Email
qmujawar@exchange.hsc.mb.ca
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric CF Patients
We'll reach out to this number within 24 hrs